Delcath Systems (DCTH) Scheduled to Post Earnings on Monday

Delcath Systems (NASDAQ:DCTH) will be announcing its earnings results after the market closes on Monday, August 5th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.43). Delcath Systems had a negative net margin of 1,080.72% and a negative return on equity of 290.07%. The company had revenue of $3.14 million during the quarter, compared to the consensus estimate of $3.70 million. On average, analysts expect Delcath Systems to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Delcath Systems Price Performance

NASDAQ DCTH opened at $8.12 on Friday. Delcath Systems has a 1 year low of $2.25 and a 1 year high of $9.18. The company has a market capitalization of $225.62 million, a PE ratio of -3.06 and a beta of 0.64. The company has a fifty day moving average of $7.80 and a two-hundred day moving average of $5.94.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. HC Wainwright upped their price objective on shares of Delcath Systems from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday, May 15th. Stephens assumed coverage on shares of Delcath Systems in a research note on Tuesday, May 14th. They set an “overweight” rating and a $25.00 target price for the company. Finally, Craig Hallum assumed coverage on shares of Delcath Systems in a research note on Friday, June 28th. They set a “buy” rating and a $18.00 target price for the company. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Delcath Systems has a consensus rating of “Moderate Buy” and an average target price of $19.83.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.